A $50 million check is the clearest signal yet that Novartis believes VAV1 degradation works in humans. Monte Rosa Therapeutics triggered that milestone payment on September 8, 2026, when Novartis enrolled the first patient in a global Phase 2 study of MRT-6160 (DDY391) in Sjögren’s disease. The molecular glue degrader targets VAV1, a signaling protein involved in lymphocyte activation, and its move into Phase 2 means the program has cleared Phase 1 safety without stopping.
The payment sits inside a much larger bet. Novartis licensed VAV1 molecular glue degraders exclusively from Monte Rosa in late 2024 for $150 million upfront, with up to $2.1 billion in development, regulatory, and sales milestones attached. The $50 million now landing is the first of those downstream payments to convert, which means Monte Rosa’s balance sheet gets a meaningful cash injection while Novartis, not Monte Rosa, runs and funds the trial from here.
Sjögren’s disease is a reasonable place to test an immunology-focused degrader. The condition drives chronic inflammation through autoreactive B and T cells, and VAV1 sits upstream in the signaling cascade that keeps those cells active. Approved options for Sjögren’s remain limited, with disease-modifying candidates from multiple companies still in mid-to-late development. Novartis conducting this study globally raises the enrollment ceiling and positions MRT-6160 for a broad regulatory path if Phase 2 reads out favorably.
For trial watchers, the number to track next is not the milestone but the Phase 2 design itself: what endpoints Novartis selected, whether the primary measure is symptom-based or biomarker-driven, and how long the treatment period runs. Degrader programs live or die on proof of target engagement in humans, and a Phase 2 in an autoimmune setting will generate that pharmacodynamic data whether or not it hits clinical endpoints. That readout, whenever it comes, will tell the field far more than this week's enrollment news.
Source link: https://www.sec.gov/Archives/edgar/data/1826457/000119312526384360/glue-20260908.htm
Jon Napitupulu is Director of Media Relations at The Clinical Trial Vanguard. Jon, a computer data scientist, focuses on the latest clinical trial industry news and trends.
